Certara/$CERT
1D1W1MYTD1Y5YMAX
Capital at risk
About Certara
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
- Ticker
- $CERT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,546
- Headquarters
- Radnor, United States
- Website
- www.certara.com
Certara Metrics
BasicAdvanced
$1.4B
-
-$0.43
1.41
-
Price and volume
Market cap
$1.4B
Beta
1.41
52-week high
$13.88
52-week low
$4.45
Average daily volume
2.4M
Financial strength
Current ratio
2.551
Quick ratio
2.328
Long term debt to equity
0.306
Total debt to equity
0.312
Interest coverage (TTM)
0.60%
Profitability
EBITDA (TTM)
94.25
Gross margin (TTM)
61.61%
Net profit margin (TTM)
-16.22%
Operating margin (TTM)
2.87%
Effective tax rate (TTM)
-57.80%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
0.77%
Return on equity (TTM)
-2.21%
Valuation
Price to revenue (TTM)
3.419
Price to book
1.44
Price to tangible book (TTM)
-14.38
Price to free cash flow (TTM)
26.426
Free cash flow yield (TTM)
3.78%
Free cash flow per share (TTM)
0.345
Growth
Revenue change (TTM)
11.09%
Earnings per share change (TTM)
-997.74%
3-year revenue growth (CAGR)
6.20%
3-year earnings per share growth (CAGR)
53.42%
What the Analysts think about Certara
Analyst ratings (Buy, Hold, Sell) for Certara stock.
Analyst projections of the future price of Certara stock.
Bulls say / Bears say
Software is showing stronger momentum than the group overall: second-quarter software revenue rose 4% and software bookings rose 9%, while software reached 53% of revenue. Management also expects software growth at or above the top end of its 0%–4% 2026 range, helped by the shift from desktop products to the cloud. (Certara, The Motley Fool)
The sale of the Regulatory and Medical Writing business leaves Certara more focused on biosimulation, clinical evidence and software. A workforce reduction affecting about 5% of employees is expected to deliver roughly $13 million in annualised savings, which could support margins once the restructuring is absorbed. (Certara, Certara)
Certara is positioning itself at the intersection of biosimulation, regulatory science and artificial intelligence. Its NVIDIA partnership and renewed four-year EMA and ECDC framework contract could deepen its role in AI-enabled drug development and real-world evidence as regulators adopt more data-driven methods. (Certara, Certara)
The recovery is not yet broad-based: second-quarter services revenue fell 3% and services bookings fell 6%, leaving total revenue up just 1%. Management expects services growth at or below the low end of its 2026 range, so weak execution there could continue to offset the software improvement. (Certara, The Motley Fool)
Profitability remains fragile during the transformation: Certara reported a $6.1 million continuing-operations loss in the second quarter, versus a profit a year earlier, while adjusted EBITDA fell 3%. Full-year adjusted EBITDA margin guidance was reduced to 29%–31% from 30%–32%, partly because divestiture-related stranded costs remain. (Certara, The Motley Fool)
The AI and software strategy is still an execution bet rather than a proven growth engine. Certara has announced an NVIDIA platform partnership, but current guidance is only for 0%–4% revenue growth and the company is still changing its services go-to-market model, creating a risk that investment and organisational disruption arrive before meaningful acceleration. (Certara, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 27 Sept 2026.
Certara Financial Performance
Revenues and expenses
Certara Earnings Performance
Company profitability
Upcoming events
No upcoming events
Certara News
AllArticlesVideos
Funds containing Certara
AllUSDEURGBP
Fund name | Fund size | $CERT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.11% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.11% |
iShares Healthcare Innovation£DRDR | £1B | 0.11% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.06% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.